- Home
- TLS vs PLX Comparison
TLS vs PLX Comparison
Compare TLS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- PLX
- Stock Information
- Founded
- TLS 1969
- PLX 1993
- Country
- TLS United States
- PLX United States
- Employees
- TLS N/A
- PLX N/A
- Industry
- TLS EDP Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLS Technology
- PLX Health Care
- Exchange
- TLS Nasdaq
- PLX Nasdaq
- Market Cap
- TLS 198.1M
- PLX 160.2M
- IPO Year
- TLS 2020
- PLX 1998
- Fundamental
- Price
- TLS $2.50
- PLX $2.61
- Analyst Decision
- TLS Buy
- PLX Strong Buy
- Analyst Count
- TLS 6
- PLX 1
- Target Price
- TLS $4.13
- PLX $15.00
- AVG Volume (30 Days)
- TLS 350.7K
- PLX 619.8K
- Earning Date
- TLS 05-09-2025
- PLX 05-09-2025
- Dividend Yield
- TLS N/A
- PLX N/A
- EPS Growth
- TLS N/A
- PLX N/A
- EPS
- TLS N/A
- PLX 0.04
- Revenue
- TLS $108,272,000.00
- PLX $53,399,000.00
- Revenue This Year
- TLS $33.75
- PLX $67.17
- Revenue Next Year
- TLS $27.97
- PLX $55.31
- P/E Ratio
- TLS N/A
- PLX $71.21
- Revenue Growth
- TLS N/A
- PLX N/A
- 52 Week Low
- TLS $1.89
- PLX $0.82
- 52 Week High
- TLS $5.03
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- TLS 46.60
- PLX 58.76
- Support Level
- TLS $2.42
- PLX $2.55
- Resistance Level
- TLS $2.57
- PLX $2.66
- Average True Range (ATR)
- TLS 0.16
- PLX 0.15
- MACD
- TLS 0.04
- PLX 0.02
- Stochastic Oscillator
- TLS 86.73
- PLX 90.20
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.